Format

Send to

Choose Destination
J Clin Lipidol. 2019 Nov - Dec;13(6):979-988.e10. doi: 10.1016/j.jacl.2019.10.004. Epub 2019 Oct 14.

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.

Author information

1
University of Iowa, Iowa City, IA, USA. Electronic address: jennifer-g-robinson@uiowa.edu.
2
Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.
3
Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
4
The Sterling Research Group, Cincinnati, OH, USA.
5
Research Program Unit, Clinical and Molecular Metabolism, University of Helsinki, Finland.
6
University of Edinburgh, Edinburgh, UK.
7
Sanofi, Clinical Development, R&D, Montpellier, France.
8
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
9
Sanofi, Chilly-Mazarin, France.
10
Harvard Clinical Research Institute, Boston, MA, USA.

Abstract

BACKGROUND:

Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9).

OBJECTIVE:

Changes in PCSK9, alirocumab, and low-density lipoprotein cholesterol (LDL-C) levels were assessed after treatment with alirocumab at doses of 75 or 150 mg every 2 weeks (Q2W).

METHODS:

Data were analyzed from 4 phase 3 trials (MONO; COMBO II; FH I; LONG TERM); all but MONO enrolled patients on statins. Three trials evaluated alirocumab 75 mg Q2W, with possible dose increase to 150 mg Q2W at week 12 based on week 8 LDL-C; LONG TERM studied alirocumab 150 mg Q2W.

RESULTS:

Patients on background statin therapy had higher mean baseline free PCSK9 concentrations vs patients not on statin. After alirocumab administration, increased alirocumab concentrations were associated with dramatic reductions in circulating free PCSK9, resulting in significant LDL-C reductions and a corresponding increase in inactive PCSK9:alirocumab complex. Alirocumab dose increase was associated with a further lowering of PCSK9 and LDL-C. Patients with higher baseline LDL-C levels (>160 mg/dL) were more likely to have their dose increased. LDL-C reductions with alirocumab were consistent between patients with baseline PCSK9 levels above or below the median when the dose increase strategy was used. When started as alirocumab 150 mg Q2W, patients with PCSK9 levels above vs below the median had a greater LDL-C reduction.

CONCLUSIONS:

Alirocumab-induced changes in PCSK9 and LDL-C levels were consistent with the known physiologic relationship between PCSK9, LDL receptor, and LDL-C levels, as well as statin-induced increases in PCSK9 production.

KEYWORDS:

Cardiovascular; Clinical trial; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Pharmacokinetic

PMID:
31708410
DOI:
10.1016/j.jacl.2019.10.004
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center